McDermott Advises Corlieve Therapeutics on the Sale of its Lead Program to uniQure

McDermott Will & Emery has advised Corlieve Therapeutics on its sale to uniQure, with its lead program, a gene therapy approach to treat Temporal Lobe Epilepsy (TLE), the most common form of focal epilepsy.

Corlieve Therapeutics is a biotechnology company focused on bringing novel therapeutic options to patients with severe neurological disorders.

uniQure is a leading gene therapy company advancing transformative therapies for patients with severe medical needs.

The McDermott team that advised Corlieve Therapeutics comprised:

• Emmanuelle Trombe, partner, Katya Ascher, counsel, Laëtitia de Dinechin and Pascaline Sagot, associates, on Corporate and Life Sciences aspects ;
• Heidi Steele, partner in Chicago, on securities aspects ;
• Côme de Saint-Vincent, associate, on tax aspects, and
• Sabine Naugès, partner, and Charlotte Michellet, counsel, on Public Law aspects.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective — and often unexpected — solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.